Section Pharmacotherapy, Department of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Research and Expertise Centre in Pharmacotherapy Education (RECIPE), Amsterdam, The Netherlands.
Clin Transl Sci. 2022 Sep;15(9):2206-2217. doi: 10.1111/cts.13354. Epub 2022 Jul 2.
An accurate estimated glomerular filtration rate (eGFR) is essential in drug dosing. This study demonstrates the limitations of indexed (ml/min/1.73 m ) and de-indexed (ml/min) eGFR based drug dosing in patients with obesity or underweight. This systematic study aimed to determine the most appropriate approach to estimate the GFR for standardized eGFR based drug dosing in these patients. (Raw) data of 12 studies were selected to investigate the accuracy and bias of both the indexed and de-indexed estimations of the Modification of Diet in Renal Disease (MDRD) study equation and the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI), and of the Cockcroft-Gault (CG) in patients with obesity or underweight. Accuracy was calculated as the proportion of eGFR values within 30% of the measured GFR (P30) using an inert tracer (e.g., iohexol, inulin, Cr-EDTA, or iothalamate clearance). An accuracy of at least 80% was considered acceptable. GFR values estimated with the CG, MDRD, and CKD-EPI differ significantly within a patient with obesity or underweight regardless of whether it is indexed or de-indexed. All studies, with two exceptions, show that all three equations are inaccurate for patients with underweight or class II obesity (P30: 55%-94%). De-indexing eGFR improves not or modestly the accuracy, and mostly remains below the 80% (P30: 62%-100%). CG was highly inaccurate in obese and underweight patients (P30: 7%-82%). Although these results show that CG is obsolete, the accuracy of MDRD and CKD-EPI is low in patients with obesity or underweight and de-indexing is not the solution. Better education and more accurate methods for appropriate drug dosing (e.g., measured GFR with inert tracer, therapeutic drug monitoring, or 24-h creatinine clearance) are recommended.
准确的估算肾小球滤过率(eGFR)对于药物剂量调整至关重要。本研究旨在探讨肥胖或消瘦患者中,基于指数(ml/min/1.73m )和非指数(ml/min)eGFR 的药物剂量调整存在的局限性。本系统研究旨在确定针对这些患者,基于标准化 eGFR 进行药物剂量调整时,最适合的估计 GFR 的方法。本研究共纳入 12 项研究的原始数据,旨在评估改良肾脏病饮食研究(MDRD)方程和慢性肾脏病流行病学合作研究(CKD-EPI)方程以及 Cockcroft-Gault(CG)公式在肥胖或消瘦患者中指数和非指数估计的准确性和偏倚。准确性通过测量肾小球滤过率(GFR)的惰性示踪剂(如 iohexol、inulin、Cr-EDTA 或 iothalamate 清除率)内 eGFR 值的比例(P30)来计算,P30 表示 eGFR 值在测量 GFR 的 30%以内的比例。P30 值至少为 80%被认为是可接受的。无论是否进行指数化,肥胖或消瘦患者中 CG、MDRD 和 CKD-EPI 估计的 GFR 值均存在显著差异。除了两项研究外,所有研究均表明,所有三种方程在体重不足或 II 度肥胖患者中都不准确(P30:55%-94%)。非指数化 eGFR 可改善或适度改善准确性,但大多仍低于 80%(P30:62%-100%)。CG 在肥胖和消瘦患者中的准确性较差(P30:7%-82%)。虽然这些结果表明 CG 已过时,但 MDRD 和 CKD-EPI 在肥胖或消瘦患者中的准确性较低,并且非指数化并非解决方案。建议采用更好的教育和更准确的方法来进行适当的药物剂量调整(如惰性示踪剂测量 GFR、治疗药物监测或 24 小时肌酐清除率)。